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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
that primarily affects the motor system and presents with progressive
muscle weakness. Most patients survive for only 2-5 years after
disease onset, often due to failure of the respiratory muscles. ALS is a
familial disease in ∼10% of patients, with the remaining 90%
developing sporadic ALS. Over the past decade, major advances
have been made in our understanding of the genetics and
neuropathology of ALS. To date, around 20 genes are associated
with ALS, with the most common causes of typical ALS associated
with mutations in SOD1, TARDBP, FUS and C9orf72. Advances in
our understanding of the genetic basis of ALS have led to the creation
of different models of this disease. The molecular pathways that
have emerged from these systems are more heterogeneous
than previously anticipated, ranging from protein aggregation and
defects in multiple key cellular processes in neurons, to dysfunction of
surrounding non-neuronal cells. Here, we review the different model
systems used to study ALS and discuss how they have contributed to
our current knowledge of ALS disease mechanisms. A better
understanding of emerging disease pathways, the detrimental
effects of the various gene mutations and the causes underlying
motor neuron denegation in sporadic ALS will accelerate progress in
the development of novel treatments.
KEYWORDS:C. elegans, Fruit fly, Motor neuron, Neurodegeneration,
Zebrafish, iPSCs
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
that primarily affects the motor neurons (MNs) in the motor cortex,
brainstem and spinal cord, resulting in progressive muscle weakness
(Rowland and Shneider, 2001). It usually has a focal onset,
presenting with unilateral limb weakness or with bulbar (Box 1)
dysfunction, and it has a tendency to propagate within the motor
system network. In the Western world, ALS has an incidence rate of
1-2 individuals per 100,000 per year and a prevalence of 4-8 per
100,000 (Logroscino et al., 2010). The lifetime risk of developing
ALS is estimated to be 1 in 400 (Johnston et al., 2006). In ∼10% of
ALS patients, the disease runs in the family (familial ALS). The
remaining 90% of patients are classified as having sporadic ALS,
although causative mutations have been identified in 5-10% of cases
(Al-Chalabi et al., 2017; Debray et al., 2013).
ALS usually presents with muscle weakness in limb muscles in
∼2 out of 3 patients or in bulbar muscles in around 1 out of 3
patients (Rowland and Shneider, 2001). Rare disease presentations
include weakness in respiratory or axial muscles (Swinnen and
Robberecht, 2014). Muscle weakness is typically accompanied by
hyper-reflexia, the wasting of muscles and the occurrence of
fasciculations due to combined upper and lower motor neuron
involvement (Box 1). In about 50% of cases, the degenerative
process extends to the frontal and anterior temporal lobe, giving rise
to a variable degree of executive dysfunction (Box 1), language
impairments or behavioural changes. Approximately 10% of
affected individuals develop frontotemporal dementia (FTD,
Box 1).
ALS is diagnosed clinically, based on the recognition of both
upper motor neuron symptoms (including hyper-reflexia, slowing
of fast movements and increased muscle tone) and lower motor
neuron signs (such as fasciculations and muscle wasting), in the
presence of a progressively worsening disease and in the absence
of other pathologies that could explain symptoms. ALS causes
relentlessly progressive muscle weakness in most patients, and its
effects on respiratory muscles limit survival to 2-5 years after
disease onset. The only approved drug for ALS is riluzole, which
has a limited but significant effect on patient survival (Bensimon
et al., 1994). Although riluzole has different mechanisms of action,
its protective effects in ALS are believed to be mediated by the
inhibition of glutamate release, counteracting excitotoxicity (Box 2)
(Doble, 1996). However, the standard treatment for ALS remains
multidisciplinary care, including nutritional and respiratory support
and symptom management.
Disease-causing gene mutations have been identified in ∼80% of
patients with familial ALS, and these mutations are typically
inherited in an autosomal dominant manner (Al-Chalabi et al.,
2017). These mutations are also present in 5-10% of patients with
sporadic (non-familial) ALS (Al-Chalabi et al., 2017; Debray et al.,
2013); however, the basis of ALS remains unknown in the majority
of cases. Over 20 genes have been linked to ALS so far, with more
expected in the future (Al-Chalabi et al., 2012). The most common
ALS disease-causing gene mutations are found in: C9orf72 (which
encodes chromosome 9 open reading frame 72), it is responsible
for 10-15% of all ALS and contains a hexa nucleotide repeat
expansion; SOD1 (superoxide dismutase 1), responsible for 2% of
ALS; TARDBP (TAR DNA-binding protein 43), responsible for
0.9% of ALS; and FUS (fused in sarcoma), responsible for 0.7% of
ALS (Al-Chalabi et al., 2017; Renton et al., 2014). Many other less-
frequent genetic mutations have also been associated with ALS,
including mutations in UBQLN2 (ubiquilin 2), OPTN (optineurin),
VCP (valosin-containing protein) and TBK1 (TANK-binding kinase
1) (Al-Chalabi et al., 2017; Renton et al., 2014). At the cellular
level, ALS pathology is characterized by axonal retraction, loss of
cell bodies of the upper and lower motor neurons, occurrence of
astrogliosis and microgliosis, and by ubiquitin-positive inclusions
in surviving neurons (Fig. 1) (Saberi et al., 2015). In ∼95% of
patients, these inclusions are positive for the RNA-binding
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protein TDP-43. TDP-43 pathology is found in most ALS patients,
and rare mutations in its gene (TARDBP) can cause ALS. It is
therefore considered a key disease protein in ALS (Saberi
et al., 2015).
The clinical manifestation of ALS is also highly variable, in terms
of its age at onset, site of onset, disease progression, relative upper
versus lower MN involvement, and in the occurrence of FTD. Even
in families with a monogenetic cause of ALS, disease presentation is
highly variable, suggesting that important disease-modifying
factors exist (Regal et al., 2006). It is therefore clear that we need
a better understanding of ALS disease mechanisms to identify
potential therapeutic targets. Various disease models have already
been developed to investigate ALS disease pathways. These models
aim to recapitulate neuropathological or genetic aspects of the
disease to uncover the molecular players involved in pathology
that might be amenable to therapeutic intervention. Small-animal
models, such as Caenorhabditis elegans, Drosophila and zebrafish
can be used for unbiased forward genetic screens. Rodent models
are considered to mimic human disease more closely and can be
valuable for unravelling pathogenic mechanisms and for proof-of-
concept studies. Induced pluripotent stem cells (iPSCs) and induced
neurons (iNs) have also recently been used to model in vitro human
neurodegenerative disorders. This reprogramming of somatic cells
from patients with ALS is considered to be a valuable contribution to
the researcher’s toolbox (Matus et al., 2014).
Translation of findings from model systems to the clinic has
been unsuccessful so far (Mitsumoto et al., 2014). Many of the
therapeutic strategies were based on single study observations in
rodent mutant SOD1 models and subsequently failed in a mostly
sporadic ALS population. However, in recent years, our insights
into the pathogenesis of MN degeneration have greatly improved.
The heterogeneity in its genetic causes offers tremendous
opportunities for creating novel disease models and for
mechanistic studies. In this Review, we summarize the emerging
new disease mechanisms identified using these different new model
systems and discuss the most important translational opportunities
and challenges.
Genes and pathways in ALS
Advances in our understanding of the genetics and neuropathology
of ALS underpin much of our current knowledge of this disease.
The discovery of mutations in SOD1 in 1993 heralded the era of
ALS disease modelling (Rosen et al., 1993). SOD1 is a cytosolic
enzyme that catalyses the detoxification of superoxide, but mis-
sense mutations in SOD1 do not seem to cause ALS by a loss of
dismutase activity. Instead, a toxic gain-of-function is thought to
underlie the disease-associated role of this protein (Cleveland and
Rothstein, 2001). In the following years, TDP-43 was identified as a
major constituent of the ubiquitin-positive aggregates found in the
MNs of ALS patients (as well as in the MNs of ∼50% of cases of
FTD in the absence of ALS) (Neumann et al., 2006). In addition,
disease-causing mutations were found in the TDP-43-encoding
gene (TARDBP) (Kabashi et al., 2008; Sreedharan et al., 2008;
Van Deerlin et al., 2008). Not long thereafter, mutations in FUS
(Kwiatkowski et al., 2009; Vance et al., 2009) and C9orf72
(DeJesus-Hernandez et al., 2011; Renton et al., 2011) were
discovered. TDP-43 and FUS are RNA- and DNA-binding
proteins that play a role in numerous cellular processes, including
transcription, splicing, microRNA maturation, RNA transport and
stress granule formation (Lagier-Tourenne and Cleveland, 2009). In
line with their nuclear and cytoplasmic functions, TDP-43 and FUS
can shuttle between the nucleus and the cytoplasm, but in basal
conditions they are predominantly nuclear. The cytoplasmic
mislocalization of TDP-43 and FUS in cytoplasmic protein
aggregates and their subsequent nuclear depletion is an important
hallmark of ALS. The nuclear loss of TDP-43 and FUS function,
their cytoplasmic aggregation and aggregate-associated cytotoxicity
are believed to contribute to ALS pathogenesis (Lagier-Tourenne
and Cleveland, 2009; Liu et al., 2017).
For C9orf72mutations, which consist of an expanded GGGGCC
hexanucleotide repeat in the first intron, three putative disease
mechanisms have been suggested: reduced C9orf72 protein
formation due to transcription interference caused by the repeat
expansion; the formation of RNA foci by RNA that contains the
repeat expansion, leading to cell toxicity (caused by their binding
and depletion of RNA-binding proteins); and repeat-associated non-
ATG (RAN) translation of sense and antisense repeat-containing
RNA, which gives rise to aggregating dipeptide repeat (DPR)
proteins (Ash et al., 2013; Mori et al., 2013). C9orf72 has also been
recently implicated in the initiation of autophagy (Sellier et al.,
2016; Webster et al., 2016), but how this relates to MN degeneration
remains unclear.
Box 1. Glossary of clinical terms
Bulbar: refers to muscles innervated by the ‘bulbus’ or brainstem via the
cranial nerves, i.e. muscles of the face, throat and tongue required for
articulation, chewing and swallowing.
Executive dysfunction: disruption of the efficiency of executive
functions, such as attention, planning, problem-solving and abstraction.
Fasciculations: spontaneous muscle twitches of individual motor units
caused by uncontrolled discharges in motor axons.
Frontotemporal dementia (FTD): dementia syndrome caused by
degeneration of cortical neurons in the frontal and anterior temporal
lobes. It can present with changes in behaviour or language dysfunction.
Lower motor neurons: motor neurons located in the brainstem nuclei
and in the ventral horn of the spinal cord, which send their axons to the
muscles. Clinical signs of lower motor neuron loss include: weakness,
muscle wasting and fasciculations.
Upper motor neurons: motor neurons located in the motor cortex,
sending commands to lowermotor neurons. Clinical signs of uppermotor
neuron loss include: increasedmuscle tone, hyperreflexia and slowing of
voluntary movements.
Box 2. Glossary of terms linked to ALS pathophysiology
Astrogliosis: proliferation and activation of astrocytes surrounding
diseased motor neurons.
Excitotoxicity: neuronal toxicity induced by excessive stimulation of
glutamate receptors. Motor neurons have been shown to be particularly
vulnerable to AMPA receptor stimulation.
Karyopherins: a family of proteins involved in transporting molecules
between the cytoplasm and the nucleus through nuclear pores.
Microgliosis: proliferation and activation of microglial cells surrounding
diseased motor neurons.
Ran-mediated nucleocytoplasmic transport: GTP-binding nuclear
protein Ran is a GTPase that is activated by a GTPase-activating protein
(RanGAP), leading to the conversion of RanGTP to RanGDP. The
conversion of RanGDP to RanGTP is mediated by RCC1, the nucleotide
exchange factor for Ran. The nucleocytoplasmic gradient of Ran drives
transport across the nucleocytoplasmic membrane through interactions
with karyopherins loaded with cargo.
Stress granules: membrane-less cytoplasmic granules of mRNA and
RNA-binding proteins formed upon stress to halt translation and to
protect mRNAs from damage.
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Fig. 1. See next page for legend.
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In recent years, mutations in several other genes have been
discovered in ALS, most of which are inherited in an autosomal
dominant manner. Although many of these mutations are not
frequently encountered, they hint at important disease pathways
involved in MN vulnerability and degeneration (Fig. 1). Some of
the genes function in protein degradation pathways, in line with an
important role for impaired proteostasis in ALS. They include
ubiquilin 2 (UBQLN2) (Deng et al., 2011), which links the
ubiquination machinery to the proteasome, and also optineurin
(OPTN) (Maruyama et al., 2010), TANK-binding kinase 1 (TBK1)
(Cirulli et al., 2015; Freischmidt et al., 2015), valosin-containing
protein (VCP) (Johnson et al., 2010) and p62/sequestosome 1
(SQSTM1) (Fecto et al., 2011; Rubino et al., 2012), which are
important for cargo recognition and cargo delivery to the
autophagosome. TBK1 can also phosphorylate OPTN and p62,
further supporting their intrinsic connections (Richter et al., 2016).
Other ALS-associated proteins affect vesicle transport and sorting,
such as charged multivesicular body protein 2B (CHMP2B)
(Skibinski et al., 2005), which functions in the sorting of
endosomal ubiquinated cargoes into multivesicular bodies, and
VAMP-associated protein B and C (VAPB) (Nishimura et al.,
2004).
In addition to TARDBP and FUS, a number of other genes that
encode RNA-binding proteins (RBPs) are mutated in ALS. Their
encoded proteins function in RNA metabolism and in stress granule
formation. For example, intermediate repeat lengths in ataxin 2
(ATXN2) (Elden et al., 2010; Van Damme et al., 2011) and
mutations in heterogeneous nuclear ribonucleoprotein A1 and
A2B1 (hnRNPA1/A2B1) (Kim et al., 2013) are linked to ALS. These
RBPs have several features in common. They shuttle between the
nucleus and cytoplasm, undergo liquid-liquid phase separation,
fulfil important roles in the nucleus and are involved in cytoplasmic
stress granule formation (Liu et al., 2017). Angiogenin (ANG),
which has also been implicated in ALS, is a mediator of blood vessel
formation and also functions as a ribonuclease that hydrolyzes
cellular tRNAs (Gao and Xu, 2008).
Other genetic mutations associated with ALS underscore the
importance of cytoskeletal organization and axonal transport for
MN health. Mutations in genes encoding cytoskeletal proteins,
such as tubulin α 4A (TUBA4A) (Smith et al., 2014), neurofilament
heavy chain (NEFH) (Al-Chalabi et al., 1999) or profilin 1 (PFH1)
(Wu et al., 2012), which is responsible for actin polymerization,
suggest that the destabilization of axonal filaments is important.
ALS-associated mutations in the dynactin subunit 1 gene (DCTN1)
(Puls et al., 2003) also indicate the involvement of the axonal
transport machinery in disease pathogenesis. Two recently
discovered ALS-associated genes, chromosome 21 open reading
frame 2 (C21orf2) (van Rheenen et al., 2016) and NIMA-related
kinase 1 (NEK1) (Kenna et al., 2016) are involved in cilia
formation, but also interact with each other in a complex involved
in DNA repair. It is not yet known how these genes contribute to
ALS pathogenesis.
The many genetic mutations that are currently associated with
ALS and that are found in ALS patients with varying prevalence,
indicate that the biological pathways that can contribute to MN
degeneration are more heterogeneous than previously anticipated.
Disease models for many of the recently discovered genes are
underway and are expected to shed light on the respective disease
mechanisms in the different genetic subtypes of ALS. Hopefully,
this will also reveal common pathways relevant to all forms of ALS.
Models of ALS
To identify novel therapeutic targets for ALS, it is essential to have a
much better understanding of the disease mechanisms that lead to
MN degeneration. To investigate these mechanisms, researchers are
modelling certain aspects of ALS in a range of model systems,
guided by recent insights into its genetic and molecular basis, to
shed light on the complex process of MN degeneration. Such model
systems vary from in vitro biochemical systems, to cell culture
systems, invertebrates and non-mammalian vertebrates, and extend
to rodent models, and more recently, to human patient-derived stem
cell models.
Each of these model systems has its advantages, as well as its
limitations, as summarized in Fig. 2. In recent years, the availability
of patient-derived stem cell models (Matus et al., 2014), has opened
up new avenues for ALS research and provides a good balance
between throughput and relevance for human disease. However, the
translational value of each of the model systems remains unclear, as
examples of successful translation to patients are still lacking. Yet, it
remains possible that a cross-model approach, in which novel
disease mechanisms identified in less-complex systems and later
validated in more-complex models as well as in human cells or
samples, have a higher chance of successful translation to the clinic.
Below, we discuss the progress and possibilities of ALS disease
models and provide examples of important insights based on these
models. Table 1 gives an overview of existing model systems for the
different genetic subtypes of ALS.
Cellular systems
As discussed earlier, many of the genetic mutations associated with
ALS lead to the production of aberrant proteins. A common feature
of these ALS disease-associated proteins is their propensity to
misfold and aggregate. In vitro oligomerization and aggregation
assays help us to understand the biophysical principles of protein
Fig. 1. ALS disease pathology and proposed disease mechanisms. At the
level of cell pathology, ALS is characterized by axonal retraction and cell body
loss of upper and lower motor neurons, surrounded by astrogliosis and
microgliosis (see Box 2), with ubiquitin- and p62-positive inclusions in surviving
neurons. Proposed disease mechanisms contributing to motor neuron
degeneration are: (1) Alterations in nucleocytoplasmic transport of RNA
molecules and RNA-binding proteins. (2) Altered RNA metabolism: several
important RNA-binding proteins become mislocalized in ALS, with cytosolic
accumulation and nuclear depletion. The nuclear depletion causes defects in
transcription and splicing. Some RNA-binding proteins can undergo liquid-
liquid phase separation and can be recruited to stress granules (TDP-43, FUS,
ATXN2, hnRNPA1/A2). Altered dynamics of stress granule formation or
disassembly can propagate cytoplasmic aggregate formation. (3) Impaired
proteostasis with accumulation of aggregating proteins (TDP-43, FUS, SOD1,
DPRs). Overload of the proteasome system and reduced autophagy may
contribute and/or cause this accumulation. (4) Impaired DNA repair: two
recently identified ALS genes (see main text for details) work together in DNA
repair, suggesting that impaired DNA repair could also contribute to ALS
pathogenesis. (5) Mitochondrial dysfunction and oxidative stress: several ALS-
related proteins (SOD1, TDP-43, C9orf72) can enter mitochondria and disrupt
normal functioning, with increased formation of reactive oxygen species (ROS)
as a consequence. (6) Oligodendrocyte dysfunction and degeneration, leading
to reduced support for motor neurons. (7) Neuroinflammation: activated
astrocytes and microglia secrete fewer neuroprotective factors and more
toxic factors. (8) Defective axonal transport: several ALS-related mutations
cause disorganization of the cytoskeletal proteins and disrupt axonal
transport. (9) Defective vesicular transport: several ALS-related proteins
(VABP, ALS2, CHMP2B, UNC13A) are involved in vesicular transport,
suggesting that impaired vesicular transport contributes to ALS
pathogenesis. (10) Excitotoxicity: loss of the astroglial glutamate transporter
EAAT2 causes accumulation of extracellular glutamate, which causes
excessive stimulation of glutamate receptors (e.g. AMPA receptors) and
excessive calcium influx.
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aggregation. Many of the ALS-associated proteins contain prion-
like domains, which promote aggregation (Boeynaems et al.,
2016b). More recently, low-complexity or intrinsically disordered
domains, which are present in many ALS-associated proteins, have
been found to mediate the process of liquid-liquid phase separation,
whereby proteins separate from a watery solution and migrate into
liquid-like droplets (Han et al., 2012; Molliex et al., 2015).
Various cell lines are used to study ALS-associated gene function
or the toxicity related to the overexpression of wild-type or mutant
proteins. Although such simple disease models do not recapitulate
the complexity of human disease, they can help to uncover
important information concerning the biological function of ALS-
associated genes and proteins. Such studies have shown, for
example, the importance of low-complexity domains in ALS
proteins for stress granule formation (Molliex et al., 2015) and the
role of C9orf72 in autophagy (Webster et al., 2016).
One cellular model that is particularly suited for modelling
cytotoxicity induced by ALS proteins is the budding yeast
Saccharomyces cerevisiae. A simple growth assay reveals that
many ALS-associated proteins cause reduced growth, which can be
used for phenotypic screening (Elden et al., 2010; Jovicic ́ et al.,
2015; Kim et al., 2014). Various genetic tools are available for
genetic screens, including libraries to perform overexpression or
single-gene deletion screens. About 30% of yeast genes have a
human homologue and several genes identified in yeast genetic
screens have been successfully validated in higher-order models.
The RNA-binding protein ATXN2 has been identified in yeast as a
modifier of TDP-43 toxicity, and as an interactor of TDP-43. This
led to the discovery of intermediate repeat expansions in ATXN2 as a
genetic risk factor for human ALS (Elden et al., 2010). ATXN2 is
recruited to stress granules, as are TDP-43 and FUS. Other stress
granule-localized proteins were found to modify TDP-43 toxicity in
yeast (Kim et al., 2014). This finding introduced the concept that
stress granule dysfunction is involved in the pathogenesis of ALS.
Another recent discovery that emerged from genetic screens in
yeast is the involvement of the nucleocytoplasmic transport
Yeast C. elegans
FastLife cycle
Rodent
models
Drosophila iPSC-derived
neurons,
iNeurons
Life span
% of genes with
human homologue
Protein conservation
Genetic screening
Compound screening
Throughput
Costs
Publications on ALS
FastFast Intermediate Slow N/A
Short ShortShort Long Long N/A
30% 75%35% >90% 100% 100%
26% 40%35% 75% 85% 100%
Yes YesYes Yes No In near future
Yes YesYes Yes No Yes
High IntermediateHigh Intermediate Low Intermediate
Low LowLow Intermediate High High
84 18477 62 >4500 153
Hypothesis
generating
Hypothesis generating
TranslationTherapeutictargetValidation
Throughput
Relevance for humans
Zebrafish
Fig. 2. Model systems in ALS research. A summary of the advantages and limitations of the different model systems – yeast,C. elegans,Drosophila, zebrafish,
rodents and iPSC-derived neurons – currently used to study ALS.
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machinery in mediating the cytotoxicity induced by dipeptide
repeat proteins (Jovicic ́ et al., 2015). The proteins involved include
several karyopherins (Box 2) and effectors of Ran-mediated
nucleocytoplasmic transport (Box 2). Pathogenic mutations have
not been identified in any of these modifiers, to date. Primary
cultures of rat or mouse MNs have often been used to investigate
MN vulnerability to a range of factors, including glutamate (Van
Damme et al., 2007) and toxic astrocytic factors released from ALS
patients or in rodent models of ALS (Nagai et al., 2007; Song et al.,
2016). More recently, primary neuronal cultures have been used to
investigate the neurotoxicity of the dipeptide repeat proteins that are
produced by RAN translation in patients with GGGGCC repeat
expansions in C9orf72 (Wen et al., 2014). These studies found that
MNs are selectively vulnerable to certain insults and that several
compounds and neurotrophic factors can enhance MN survival
in vitro (e.g. Bordet et al., 2007). Although these cellular models
only remotely mimic the disease, their merit lies in their potential to
study the role of genes involved in ALS, to assess the consequences
Table 1. Disease models of gene mutations associated with ALS
Gene
mutation
linked to ALS
Frequency
(% of total
ALS)
Putative gene
function
Disease
protein
Model system
Cells/
primary
cultures Yeast C. elegans Drosophila Zebrafish Mouse Rat
iPSCs,
iNs
C9orf72 10 Predicted to function
as GEF for small
GTPases, vesicle
transport,
autophagy,
regulator of actin
dynamics
TDP-43*, DPR ✓ ✓ ✓ ✓ ✓ ✓ X ✓
SOD1 2 Detoxification of
superoxide
radicals
SOD1 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
TARDBP 0.9 RNA metabolism TDP-43 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
FUS 0.7 RNA metabolism FUS ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
DCTN1 <0.5 Axonal transport Unknown X X X X X ✓ X X
NEFH <0.5 Neurofilament
component
Unknown X X X X X ✓ X X
VAPB <0.5 Vesicle trafficking Unknown ✓ ✓ ✓ ✓ ✓ ✓ X ✓
ALS2 <0.5 Rho GEF, vesicle
transport
Unknown ✓ X X ✓ ✓ ✓ X X
CHMP2B <0.5 Vesicle transport Unknown ✓ X X ✓ X ✓ X ✓
ANG <0.5 RNA metabolism TDP-43* ✓ X X X X X X ✓
VCP <0.5 Protein degradation TDP-43* ✓ ✓ ✓ ✓ X ✓ X ✓
OPTN <0.5 Golgi maintenance,
vesicle transport,
autophagy
TDP-43* ✓ ✓ X X ✓ X X X
SETX <0.5 DNA/RNA helicase,
RNA metabolism
Unknown ✓ ✓ X ✓ X X X ✓
ATXN2 <0.5 Golgi maintenance,
endocytosis, RNA
metabolism
TDP-43*,
ATXN2
✓ X X ✓ ✓ ✓ X ✓
UBQLN2 <0.5 Targeting of
misfolded proteins
to proteasome
TDP-43*, OPTN ✓ X X X X ✓ ✓ X
SQSTM1 <0.5 Autophagy, NFκB
activator
TDP-43* ✓ X X ✓ ✓ ✓ X X
PFN1 <0.5 Actin polymerization TDP-43*, PFN1 ✓ ✓ X X X ✓ X X
hnRNPA1/A2 <0.5 RNA metabolism
and transport
TDP-43*,
hnRNPA1/A2
✓ ✓ X ✓ X X X X
TUBA4A <0.5 Microtubule
component
Unknown X X X X X X X X
TBK1 <0.5 NFκB activator,
vesicle transport,
autophagy
Unknown X X X X X X X X
C21orf2 <0.5 Cilia formation, DNA
repair
Unknown X X X X X X X X
NEK1 <0.5 Cilia formation, DNA
repair
Unknown X X X X X X X X
*Presence of TDP-43-positive inclusions in motor neurons in the absence of mutation in the gene encoding TDP-43.
ALS2, human amyotrophic lateral sclerosis 2 ( juvenile), also known as alsin;ANG, angiogenin; ATXN2, ataxin 2;C9orf72, chromosome 9 open reading frame 72;
C21orf2, chromosome 21 open reading frame 2;CHMP2B, charged multivesicular body protein 2B; DCTN1, dynactin subunit 1;DPR, dipeptide repeat (protein);
FUS, fused in sarcoma; GEF, guanine exchange factor; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; NEFH, neurofilament heavy; NEK1, NIMA-
related kinase 1; NFκB, nuclear factor kappa B subunit; OPTN, optineurin; PFN1, profilin 1; SETX, senataxin; SOD1, superoxide dismutase 1; SQSTM1,
sequestosome 1; TARDBP, TAR DNA-binding protein 43; TBK1, TANK-binding kinase 1; TUBA4A, tubulin alpha 4A; UBQLN2, ubiquilin 2; VAPB, VAMP-
associated protein B and C; VCP, valosin-containing protein.
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of gene mutations, to model protein aggregation and to identify
disease-modifying genes or compounds in unbiased screens.
Small-animal models
A key limitation of cellular models is that they lack the complex
interplay that occurs between MNs and their surrounding
environment in a living organism. Although rodent models are
considered the gold standard for validating disease mechanisms and
for providing preclinical data on potential therapeutic targets, small-
animal models are increasingly being used to model the diverse
genetic causes of ALS. They can be generated quickly, are cheap to
maintain relative to rodent models and are amenable to genetic or
compound screening. In addition, interactions between different
genetic causes and between different genetic modifiers can be
studied in whole animals in order to identify the genetic networks
involved in neurodegeneration.
Drosophila melanogaster
By far the most widely used small-animal model of ALS is the fruit
fly, Drosophila melanogaster. The fruit fly is an attractive disease
model for several reasons. It has ∼14,000 genes on 4 chromosomes,
and about 75% of human genes have a functional orthologue in the
fly with, on average, about 40% homology (McGurk et al., 2015).
The fly has a very rapid life cycle and its lifespan is only ∼50 days.
The nervous system is also quite sophisticated and contains
approximately 100,000 neurons (Pandey and Nichols, 2011), and
there are a number of tools and assays available to study its function
(Ugur et al., 2016).
The repertoire of genetic tools available for Drosophila is
extensive: transgenic flies that overexpress a transgene of interest
or a small interfering RNA can be rapidly generated, and the
GAL4/UAS system allows for cell-specific expression or gene
knockdown. Moreover, the tools for genetic screens, created by
crossing wild-type flies to deletion stocks or to RNAi lines (which
cover ∼90% of the genome and are publicly available), and for
chemical mutagenesis are extremely efficient (Ugur et al., 2016).
Fly models overexpressing mutant human transgenes for ALS
linked to mutations in SOD1 (Watson et al., 2008), TARDBP
(Estes et al., 2011; Feiguin et al., 2009; Vanden Broeck et al.,
2013), FUS (Chen et al., 2011; Lanson et al., 2011), C9orf72
(Mizielinska et al., 2014; Xu et al., 2013), ALS2 (Takayama et al.,
2014), VAPB (Ratnaparkhi et al., 2008; Tsuda et al., 2008), VCP
(Johnson et al., 2015) and SETX (Mushtaq et al., 2016) exist.
These transgenic models for ALS show that the overexpression of
the wild-type or mutant version of each of these proteins induces
cellular toxicity. For TARDBP and FUS, both gene deficiency and
overexpression were toxic (Lanson et al., 2011; Vanden Broeck
et al., 2013). This suggests that TDP-43 and FUS are essential
proteins, with tightly regulated levels, and that minor changes in
their levels or protein sequence has far-reaching consequences for
neuronal health. Neuronal toxicity induced by expanded
GGGGCC-repeat RNA (Xu et al., 2013) and by the direct
expression of codon-optimized dipeptide repeat proteins
(Mizielinska et al., 2014) has also been shown in Drosophila. In
particular, the neuronal toxicity of the arginine-containing
dipeptide repeat proteins, proline-arginine (PR) and glycine-
arginine (GR), has been modelled in the fly (Mizielinska et al.,
2014; Tran et al., 2015; Wen et al., 2014). The transcriptional
activator protein Pur-α is a binding partner of the expanded
GGGGCC RNA, and its overexpression rescued the neuronal
toxicity induced by this repeat RNA in the fly (Xu et al., 2013).
Together with other RBPs, Pur-α is present in RNA foci and stress
granules; it also regulates stress granule dynamics and counteracts
motor neuron death induced by overexpression of mutant FUS in
primary MNs overexpressing mutant FUS (Daigle et al., 2016).
Targeted genetic screens and validation experiments inDrosophila
have also been instrumental to uncover several ALS disease
mechanisms. ATXN2 was confirmed to be a modifier of TDP-43
toxicity in the fly, as its overexpression enhanced the retinal toxicity
induced by TDP-43, while its downregulation mitigated toxicity
(Elden et al., 2010). Targeted genetic screens inDrosophila have also
identified several important players in nucleocytoplasmic transport as
modifiers of the cytotoxicity induced by GGGGGCC-repeat RNA or
by dipeptide repeat proteins (Boeynaems et al., 2016a; Freibaum
et al., 2015; Zhang et al., 2015). Experiments in yeast first pointed to a
role for stress granule dysfunction in ALS. However, an important
role for poly-(A)-binding protein (PABP) and eIF2a phosphorylation
(both involved in stress granule formation) as modifiers of TDP-43
toxicity was later confirmed in Drosophila (Kim et al., 2014).
Caenorhabditis elegans
The nematode C. elegans is also being used to study the genetic
pathways that contribute to ALS (Therrien and Parker, 2014). C.
elegans has an extremely short life cycle of only 4 days and is easy
to manipulate genetically. About 35% of human genes have worm
orthologues, typically with about 30% protein sequence homology
(Therrien and Parker, 2014). The nervous system of this nematode is
simple but very well characterized, with all 302 neurons and their
connections carefully mapped (Therrien and Parker, 2014). GFP
fusion proteins can make specific proteins visible in vivo over time,
because of the transparency of C. elegans. Moreover, many
mammalian cellular stress and survival pathways are conserved in
the worm. C. elegans models of the four main ALS-associated
genetic mutations (SOD1, C9orf72, TARDBP and FUS) have been
created (Therrien and Parker, 2014) and have contributed to several
important recent insights. For example, calcineurin was identified in a
C. elegans model of TDP-43 proteinopathy as an important
phosphatase involved in the removal of pathological C-terminal
phosphorylation of TDP-43 (Liachko et al., 2016). Another
C. elegans ALS model revealed that the N-terminal low-
complexity domain of FUS (which mediates the liquid-liquid phase
separation that allows FUS to enter liquid-like membrane-free
granules, such as stress granules) is necessary for neuronal toxicity
caused by aberrant FUS (Murakami et al., 2015). Evidence for ER
stress and disturbed Ca2+ homeostasis as modifiers of MN
degeneration was generated using C. elegans models expressing
humanmutant TDP-43 or SOD1 (Aggad et al., 2014; Jablonski et al.,
2015). Interestingly, modifying the expression levels of the ALS risk-
enhancing genes UNC13A (van Es et al., 2009) and SARM1 (van
Rheenen et al., 2016) also modified neurodegeneration in C. elegans
models of mutant TDP-43 and FUS (Veriepe et al., 2015). Moreover,
knockdown of the orthologue of dynactin 1 inC. elegans resulted in a
motor phenotype that indicates a potential role for autophagosome
transport in MN maintenance (Ikenaka et al., 2013).
Zebrafish
Zebrafish (Danio rerio), often used to study embryonic
development because of the transparency of their embryos and
their vertebrate body plan (Phillips and Westerfield, 2014), are
increasingly being used in ALS research because of the advantages
this model offers (see Fig. 2) (Patten et al., 2014). Most human
genes have a zebrafish homologue, typically with about 70%
homology in protein sequence (Phillips and Westerfield, 2014).
Zebrafish can be used for compound screening. In addition, gene
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overexpression or knockdown can be easily achieved using
injections of RNA (or cDNA) or morpholinos (a form of
antisense RNA) at the 2- to 4-cell embryonic stage. More
recently, gene-deletion strategies (such as CRISPR/Cas9) have
been used to combat the off-target effects of some morpholinos
(Gerety and Wilkinson, 2011). Stable transgenic zebrafish have
been generated for in-depth studies of disease pathogenesis in
ageing fish (with a life span of up to 2 years) (Ramesh et al., 2010).
In ALS research, transient embryonic models have been used to
model the toxic effects of ALS-associated genetic mutations. These
models, which were generated by injecting cDNA or RNA in
fertilized eggs, have provided evidence that mutant SOD1 leads to
neuronal toxicity via a gain-of-function (Sakowski et al., 2012; Van
Hoecke et al., 2012). The same models have been used to
demonstrate combined gain- and loss-of-function mechanisms for
TARDBP, FUS and C9orf72 (Armstrong and Drapeau, 2013; Ciura
et al., 2013; Hewamadduma et al., 2013; Lee et al., 2013; Schmid
et al., 2013), as both reducing and increasing gene expression levels
induced motor neuron toxicity.
Additionally, interactions between different ALS-associated genes
can be readily studied in zebrafish. Zebrafish experiments have
revealed commonalities between TDP-43- and FUS-induced MN
toxicity. For example, wild-type TDP-43 and FUS could rescue MN
toxicity induced by knockdown of the respective genes, but not the
toxicity induced by mutant SOD1 (Kabashi et al., 2011). Furthermore,
the neurotrophic factor progranulin was found to improve the MN
toxicity induced bymutant TDP-43 and FUS, but not of mutant SOD1
(Kabashi et al., 2011; Laird et al., 2010). A zebrafish morpholino-
based modifier screen identified the ephrin receptor EphA4 as a
modifier of ALS (Van Hoecke et al., 2012). The authors then
confirmed that lowering EphA4 levels has a beneficial effect on
disease progression in mutant SOD1 mice and that low EphA4 levels
are associated with milder clinical manifestations in ALS patients (Van
Hoecke et al., 2012). In mutant SOD1 zebrafish, the earliest evidence
of pathogenicity is interneuron dysfunction resulting in reduced
inhibitory input to spinal motor neurons. In a compound screening,
riluzole and apomorphine (an activator of the regulator of resistance to
oxidative stress, nuclear factor erythroid 2-related factor 2 or NRF2)
counteracted this interneuron dysfunction (McGown et al., 2013).
Stimulation of resistance to oxidative stress byNRF2 overexpression in
astrocytes also prolonged survival inmutant SOD1mice (Vargas et al.,
2008), suggesting that this pathway warrants further study in ALS.
Although the small-animal models discussed here have not yet
given rise to new therapies in patients, they play an increasingly
important role in ALS research. Owing to the speed and ease with
which transgenic lines can be generated, disease models for each of
the genetic subtypes of ALS can readily be made to facilitate in-
depth study of the interactions between the different forms. Thanks
to improved genetic engineering technologies, there is a tendency to
use fewer overexpression models and to switch to knock-in models.
In addition, unbiased genetic screens are feasible and can reveal key
disease modifiers. Compound screening is also possible, especially
in C. elegans and zebrafish. For all these reasons, these small-
animal models are particularly suited as hypothesis-generating
platforms that can reveal novel potential therapeutic targets ready
for validation in complex but low-throughput rodent models.
Rodent models of ALS
Rodent models exist for genetic mutations that are most prevalent in
ALS patients and arewidely used to study diseasemechanisms. An in-
depth discussion of all recent ALS rodent models is beyond the scope
of this article, and we refer readers to recent reviews on rodent models
for ALS-associated mutations in SOD1, TARDBP, FUS and C9orf72
for more information (Gendron and Petrucelli, 2011; Nolan et al.,
2016; Philips and Rothstein, 2015; Turner and Talbot, 2008).
Transgenic mice and rats represent the gold standard of preclinical
ALS modelling and these animal models have provided important
insights into MN degeneration pathways (Ferraiuolo et al., 2011). In
particular, mouse models in which human genomic mutant SOD1 is
overexpressed have been used intensively since the first of such
models became available in 1994 (Gurney et al., 1994) and much of
our current understanding of disease mechanisms is based on this
model. Although overexpression of the transgene is an important
limitation of these models, the significant correlation between the
expression level ofmutant SOD1 and the severity ofMN degeneration
(Alexander et al., 2004) paved the way for gene-silencing strategies
using antisense oligonucleotides (ASOs) to treat mutant SOD1-
mediated ALS (Smith et al., 2006; van Zundert and Brown, 2017).
Protein misfolding and aggregation is observed prior toMN death
in rodent models, as in ALS patients (Chattopadhyay and Valentine,
2009). A prion-like, cell-to-cell migration of misfolded SOD1,
which is secreted by MNs (Urushitani et al., 2006) and taken up by
neighbouring cells, is an emerging concept that has potentially
important therapeutic implications. Defects in protein-clearance
mechanisms might also underlie problems with protein turnover
(Ruegsegger and Saxena, 2016). Apart from overloading the
ubiquitin-proteasome system, alterations in autophagosome
formation, in vesicle transport and in lysosome fusion, to induce
the degradation of damaged proteins and organelles, have been
implicated in ALS (Cipolat Mis et al., 2016). Preclinical studies in
mutant SOD1 mice suggest that boosting autophagy could slow
down disease progression (Cipolat Mis et al., 2016; Staats et al.,
2013).
A neuroinflammatory response is common to all forms of ALS
and most likely modulates the process of neurodegeneration (Philips
and Robberecht, 2011). Cell type-specific transgenic mouse
models, using the Cre-Lox system to excise the mutant SOD1
transgene from specific cell-types, have greatly advanced our
understanding of the importance of non-neuronal cell types in
MN degeneration, such as microglia (Boillee et al., 2006),
astrocytes (Yamanaka et al., 2008) and oligodendrocytes (Kang
et al., 2013). The importance of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor-mediated excitotoxicity
inMN death has been shown in rodent models of ALS (Van Damme
et al., 2005b), with a loss of the astrocytic glutamate transporter
EAAT2 (Rothstein et al., 2005) and altered AMPA receptor subunit
composition (Van Damme et al., 2007; Van Damme et al., 2005a)
contributing to increased extracellular glutamate levels and to MN
vulnerability to glutamate stimulation, respectively.
Alterations in mitochondrial morphology, function, clearance
and transport have also been observed in mutant SOD1 mice, and
this can lead to energy failure and to oxidative stress (Shi et al.,
2010). Moreover, inhibition of the mitochondrial permeability
transition-mediated cytochrome c release, using minocycline,
resulted in a significantly longer survival of mutant SOD1 mice
(Zhu et al., 2002), an effect that was confirmed by others (Kriz et al.,
2002; Van Den Bosch et al., 2002). A subsequent trial with
minocycline in patients with ALS failed (Gordon et al., 2007);
however, the drug has not yet been tested in a population of ALS
patients with SOD1 mutations.
Studies in mutant SOD1 mice have revealed that the disease
process starts with a dying back of axons (axonopathy), characterized
by axonal retraction from neuromuscular junctions and by axonal
degeneration prior to the loss of cell bodies in the ventral horn of the
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spinal cord (Fischer et al., 2004). Alterations in cytoskeletal
organization, axonal transport of mitochondria, RNA, vesicles and
other cargoes, and changes in axonal outgrowth cues (such as EphA4
and Nogo-A) might all contribute to this axonal degeneration (Peters
et al., 2015). In linewith this idea, the protection of neuronal survival,
either by deleting the pro-apoptotic Bax gene or by inhibiting p38
MAPK, is insufficient to extend dramatically the survival of mutant
SOD1 mice (Dewil et al., 2007; Gould et al., 2006).
The mutant SOD1 rodent models have also contributed to the
concept that neurotrophic factors play a crucial role inMNdegeneration.
One example of this is vascular endothelial growth factor (VEGF). A
transgenic mousemodel in which the ‘hypoxia response element’ in the
promoter region of the Vegf gene was deleted developed an ALS-like
phenotype (Oosthuyse et al., 2001). In addition, Vegf expression was
lower in the spinal cords ofmutant SOD1mice before disease onset (Lu
et al., 2007). The phenotype of these mice improved by overexpressing
VEGF; additionally, the survival of the mutant SOD1 rat model
increased on VEGF treatment. These findings suggest that VEGF
contributes to and could modify neurodegeneration in ALS
(Storkebaum et al., 2005; Wang et al., 2016).
Rodent models remain the gold standard ALS model, because
they are a mammalian model system with a high degree of genetic
homology to humans, enabling detailed mechanistic studies with
palpable relevance to human physiology. However, they are much
more expensive to maintain and time-consuming to generate
compared with small-animal models and do not allow for testing
multiple hypotheses at the same time. Another limitation is the
inbred nature of mouse colonies, which does not reflect the human
situation and can give rise to variable results when crossbreeding
with other transgenic lines is required. Most mouse models are still
overexpression models, but by using novel genetic engineering
technologies, knock-in models will become more readily available.
Stem cell models
The ability to generate induced pluripotent stem cells (iPSCs) from
differentiated cells has opened up new avenues for ALS research. By
introducing pluripotency genes into human patient-derived cells, it is
now feasible to generate iPSCs from patients with ALS (with or
without known disease-causing gene mutations) (Matus et al., 2014).
In addition, iPSCs can be differentiated into spinal motor neurons
(Maury et al., 2015) to study the specific cell type of interest in ALS.
Direct conversion of fibroblasts into neurons has become feasible as
well (Son et al., 2011). Although the translational potential of these
ALS models remains to be proven, they seem to have many
advantages and a good balance between throughput and relevance for
the human disease (Matus et al., 2014). One of the most important
advantages of generating models from patient-derived stem cells is
that they remove the need to overexpress transgenes containing
pathogenic ALS gene mutations. In addition, they carry endogenous
gene mutations in the context of an individual patient’s genetic
background. Sporadic ALS can also bemodelled using this approach,
which is not possible in the other model systems.
The protocols for generating spinal motor neurons are improving,
but the iPSCmodels could be of greater value if robust systems were
available to generate mature MNs that innervate muscle cells
(Sances et al., 2016). Generating upper motor neurons also remains
a challenge (Sances et al., 2016). Using gene-editing techniques,
such as CRISPR/Cas9, it is possible to correct disease-causing
mutations in stem cell models and to compare patient lines to their
corrected counterpart – an important advantage of this approach,
given the considerable biological variability between different lines
(Kiskinis et al., 2014; Sances et al., 2016). Many of the first ALS
iPSC models have revealed interesting in vitro phenotypes (Matus
et al., 2014), which are valuable for mechanistic studies and for
designing novel therapeutic strategies. Several aspects of the
disease’s neuropathology are recapitulated in iPSC-derived motor
neurons, such as the aggregation and/or cytoplasmic mislocalization
of TDP-43, SOD1, FUS, and in the case of C9orf72 repeat
expansions, the formation of RNA foci and dipeptide repeat proteins
(Matus et al., 2014). Many important functional phenotypes have
already been identified in iPSC-derived spinal motor neurons,
ranging from increased cell death (Bilican et al., 2012),
neurofilamentous disorganization (Chen et al., 2014), defects in
nucleocytoplasmic transport (Zhang et al., 2015), to changes in
excitability (Kiskinis et al., 2014). An example of the latter is
provided by a study using MNs derived from patients with an A4V
mutation in SOD1. These MNs displayed reduced delayed-rectifier
potassium currents, giving rise to hyperexcitability; boosting the
currents with retigabine blocked the hyperexcitability and improved
MN survival in vitro (Wainger et al., 2014). Patient-derived cells
have also been used to confirm the importance of non-neuronal cells
in human ALS models without overexpression of mutant transgenes
(Ferraiuolo et al., 2016; Meyer et al., 2014). In addition, patient-
derived MNs have proved to be invaluable to test therapeutic
interventions, such as the use of ASOs (Lagier-Tourenne et al.,
2013; Sareen et al., 2013) and to perform compound screening
(Egawa et al., 2012). Genetic screens using CRISPR/Cas9
technology on phenotypic read-outs in iPSC-derived MNs will
hopefully be possible in the near future (Qi et al., 2017).
Expectations are high for patient-derived stem cell models. They
contain the genetic make-up of an individual who has developed
ALS, even when the actual cause of the disease is unknown. Ideally,
a component of ageing should be built into these models as well as
the complex interactions with surrounding non-neuronal cells.
Conclusions
The hitherto unsuccessful translation of findings from model
organisms to patients can be accounted for both by factors related to
the model systems and by factors related to the trial design in
patients (Mitsumoto et al., 2014). The heterogeneity in ALS causes
has been underestimated in the past and may have contributed to a
targeting of the wrong patient populations. In mice, treatments are
often started prior to disease onset, whereas patients are usually well
into their disease course before entering a trial. Yet, the most
important obstacle to develop new therapies is arguably our failure
to grasp the cause of the disease in the majority of the patients.
Nonetheless, important progress has been made in our
understanding of the genetics and neuropathology of ALS, opening
up new avenues for disease modelling research and for better
characterizing the disease pathways that contribute to ALS. Many
different models are now being generated to investigate the recently
identified ALS-associated genes, several of which seem to cluster
into functional networks. Amongst others, these include RNA
metabolism, protein degradation, vesicle transport, autophagy,
cytoskeletal organization and axonal transport. iPSC-derived MNs
expand the repertoire of ALS disease models and offer new
opportunities, particularly for modelling sporadic ALS. Many
fascinating disease mechanisms are emerging from models of ALS,
such as impairments in nucleocytoplasmic transport, alterations in
stress granule dynamics, transcriptional dysregulation, and non-
neuronal cells acting as modulators of the disease (Taylor et al., 2016).
Our progress in the availability of multiple disease models for ALS
research and in the knowledge about the biology of the disease offers
hope that robust therapeutic targets will be identified in the near future.
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